These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 13433378)

  • 21. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality.
    Rudnick MR; Goldfarb S
    Rev Cardiovasc Med; 2003; 4 Suppl 5():S28-33. PubMed ID: 14668707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetylcysteine for contrast nephropathy: more clinical science is required.
    Eddleston M; Goddard J; Bateman N
    Arch Intern Med; 2006 Aug 14-28; 166(15):1668-9; author reply 1669. PubMed ID: 16908804
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse reactions to intravenous iodinated contrast media: an update.
    Namasivayam S; Kalra MK; Torres WE; Small WC
    Curr Probl Diagn Radiol; 2006; 35(4):164-9. PubMed ID: 16814003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Water for contrast-induced nephropathy? A thirst for knowledge.
    Pate GE; Webb JG
    J Invasive Cardiol; 2003 Dec; 15(12):703-5. PubMed ID: 14660822
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of contrast media on renal function in patients with cirrhosis: a prospective study.
    Guevara M; Fernández-Esparrach G; Alessandria C; Torre A; Terra C; Montañà X; Piera C; Alvarez ML; Jiménez W; Ginès P; Arroyo V
    Hepatology; 2004 Sep; 40(3):646-51. PubMed ID: 15349903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Contrast medium induced nephropathy].
    Pintér I; Degrell P; Nagy J
    Orv Hetil; 2005 Nov; 146(48):2451-6. PubMed ID: 16408385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new animal model for testing renal tolerance of contrast agents.
    Krause W; Gilles T
    Invest Radiol; 2003 Nov; 38(11):704-11. PubMed ID: 14566180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contrast-induced nephropathy after computer tomography. Hydration and adapted contrast media dosage for the best prophylaxis].
    Haglund M; Hesselstrand R; Nyman U; Sterner G
    Lakartidningen; 2005 Oct 3-9; 102(40):2864-6, 2869-70. PubMed ID: 16255363
    [No Abstract]   [Full Text] [Related]  

  • 29. [Fundamentals on iodinated contrast media and adverse reactions].
    Feltrin GP; Zandonà M; Borile V; Rettore C; Miotto D
    Radiol Med; 2004 Apr; 107(4 Suppl 1):8-31. PubMed ID: 15323318
    [No Abstract]   [Full Text] [Related]  

  • 30. Significant statistical heterogeneity in a meta-analysis of the usefulness of acetylcysteine for prevention of contrast nephropathy.
    Faddy SC
    Am J Cardiol; 2004 Aug; 94(3):414. PubMed ID: 15276125
    [No Abstract]   [Full Text] [Related]  

  • 31. Kidneys may be tougher than you thought.
    Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812981
    [No Abstract]   [Full Text] [Related]  

  • 32. Preventing complications of radiographic contrast media: is there a role for dialysis?
    Rodby RA
    Semin Dial; 2007; 20(1):19-23. PubMed ID: 17244114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and therapy strategies for contrast-induced nephropathy.
    Toprak O; Cirit M
    Ren Fail; 2006; 28(5):365-81. PubMed ID: 16825085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Pedersen M
    J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808
    [No Abstract]   [Full Text] [Related]  

  • 35. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures.
    Schweiger MJ; Chambers CE; Davidson CJ; Blankenship J; Bhalla NP; Block PC; Dervan JP; Gasperetti C; Gerber L; Kleiman NS; Krone RJ; Phillips WJ; Siegel RM; Uretsky BF; Laskey WK
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):135-40. PubMed ID: 17139671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of contrast nephropathy from cerebral CT angiography and CT perfusion imaging.
    Josephson SA; Dillon WP; Smith WS
    Neurology; 2005 May; 64(10):1805-6. PubMed ID: 15911820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity of contrast media: an update.
    ten Dam MA; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):416-22. PubMed ID: 19011267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD.
    Jamboti J
    Nephrology (Carlton); 2007 Jun; 12(3):316. PubMed ID: 17498132
    [No Abstract]   [Full Text] [Related]  

  • 40. Ionic high-osmolar contrast medium causes oxidant stress in kidney tissue: partial protective role of ascorbic acid.
    Cetin M; Devrim E; Serin Kiliçoglu S; Ergüder IB; Namuslu M; Cetin R; Durak I
    Ren Fail; 2008; 30(5):567-72. PubMed ID: 18569939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.